Expansion and use of expanded NK cell fractions

1. A method of preparing a transplantable NK cell fraction for transplantation, in two portions, into a subject in need thereof, wherein the subject is a human subject that is greater than 18 years of age, the method comprising:

(a) ex vivo culturing a CD3-depleted NK cell fraction HLA-haploidentical or HLA-mismatched for said subject under conditions allowing for cell proliferation, wherein said conditions comprise providing nutrients, serum, IL-15 and nicotinamide in an amount between 1.0 mM to 10 mM;

(b) supplementing said CD3-depleted NK cell fraction with fresh nutrients, serum, IL-15 and nicotinamide 8-10 days following step (a) to produce an expanded CD3-depleted NK cell fraction;

(c) harvesting a first portion of said expanded CD3-depleted NK cell fraction 14 days following step (a), and harvesting a second portion of said expanded CD3-depleted NK cell fraction 16 days following step (a), wherein said first portion comprises about 50% of said expanded CD3-depleted NK cell fraction and said second portion comprises the remainder of said expanded CD3-depleted NK cell fraction,

wherein said first portion and the second portion each comprise at least 1×10 7 to 5×10 8 NK cells per kg of the subject; and

(d) washing and concentrating said first and said second portions of said expanded CD3-depleted NK cell fraction of step (c),

(e) transferring each of said washed and concentrated first and said second portions of said expanded CD3-depleted NK cell fraction to one or more culture bags,

(f) reconstituting each of said washed and concentrated first and said second portions of said expanded CD3-depleted NK cell fraction with an infusion solution, and

(g) storing each of the reconstituted first and said second portions of said expanded CD3-depleted NK cell fraction at room temperature until infusion into said subject, wherein said storing is for no later than 10 hours after final product release of each of the first and second portions of said washed and concentrated expanded CD3-depleted NK cell fraction.

2. The method of claim 1 , wherein said CD3-depleted NK cell fraction is a human NK cell fraction.

3. The method of claim 1 , wherein said ex-vivo culturing is devoid of a feeder layer.

4. The method of claim 1 , wherein said conditions for allowing for cell proliferation comprise providing 10% human serum.

5. The method of claim 1 , wherein said nutrients comprise minimal essential cell culture medium.

6. The method of claim 1 , wherein said NK cell fraction is from an HLA-haploidentical or HLA-mismatched donor having at least:

(a) HLA matching at intermediate resolution DNA-based Class 1 typing of the A and B locus of at least 2/4 class 1 allele; and

(b) absence of (MFI <1000) recipient donor-specific anti-HLA antibodies, and wherein said NK cells of step (a) comprise at least 40-90% CD56+/CD3− cells.

7. The method of claim 1 , wherein said washed and concentrated first and second portions of said expanded NK cell fraction generated by step (d) are characterized by the following parameters:

(a) at least 70% CD56+/CD3− cells;

(b) at least 70% viability;

(c) fewer than 5.0 λ105 CD3+ cells/Kg mass of patient, upon infusion;

(d) no more than 5 EU endotoxin/Kg mass of patient, upon infusion; and

(e) no Gram-positive micro-organisms.